<DOC>
	<DOC>NCT01012011</DOC>
	<brief_summary>This surveillance are to identify problems/questions regarding adverse events, factors that are considered to affect on safety and efficacy in the clinical practice of using Nexavar</brief_summary>
	<brief_title>Regulatory Post Marketing Surveillance Study on Nexavar®</brief_title>
	<detailed_description>The objectives of this surveillance are to identify problems/questions regarding the followings in the clinical practice of using Nexavar®. 1. Unknown adverse events (in particular, serious adverse events) 2. Identification of adverse events occurred in the real practice. 3. Factors that are considered to affect on safety. 4. Factors that are considered to affect on effectiveness</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Patients with diagnosis of advanced RCC or HCC and decision taken by the physician to prescribe Nexavar. Exclusion criteria must be read in conjunction with the local product information but patients who are participating in other interventional studies currently will be excluded.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>91 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Carcinoma, Hepatocellular</keyword>
	<keyword>Carcinoma, Renal Cell</keyword>
</DOC>